Welcome to our dedicated page for Maze Therapeutics SEC filings (Ticker: MAZE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Maze Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Maze Therapeutics's regulatory disclosures and financial reporting.
Maze Therapeutics director Charles J. Homcy received a grant of stock options covering 18,000 shares of common stock. The options have an exercise price of $23.58 per share and expire on June 7, 2036. They will vest and become fully exercisable on the earlier of the company’s 2027 annual stockholders meeting or June 8, 2027, subject to his continued service.
Maze Therapeutics director Nancy C. Andrews received a grant of 18,000 stock options to buy common stock. The options have an exercise price of $23.58 per share and expire on June 7, 2036. Following this grant, she holds 18,000 options.
The options will vest and become fully exercisable on the earlier of the company’s 2027 annual stockholders meeting or June 8, 2027, provided she continues serving the company through that vesting date.
Maze Therapeutics, Inc. reported the results of its 2026 annual stockholder meeting. A total of 44,660,029 shares of common stock, representing approximately 89.75% of the shares entitled to vote, were present or represented by proxy, establishing a quorum.
Stockholders elected Jason Coloma, Ph.D. and Neil Kumar, Ph.D. as directors to serve until the 2029 annual meeting, with 35,792,536 and 34,056,425 votes for, respectively, and broker non-votes recorded on both. Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 44,557,778 votes for, 728 against, and 101,523 abstentions.
Maze Therapeutics, Inc. director and CEO Jason V. Coloma reported indirect open-market sales of company common stock by two family trusts associated with him. On June 1, 2026, the Coloma Family Trust sold 6,090 shares at a weighted average price of $26.1965 per share, leaving it with 344,897 shares. The Coloma 2021 Irrevocable Trust sold 553 shares at a weighted average price of $26.2412, leaving it with 27,970 shares. A footnote states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026, indicating they were scheduled in advance rather than timed discretionarily.
Maze Therapeutics, Inc. President, R&D & CMO Harold Bernstein exercised stock options for 14,853 shares of common stock at an exercise price of $10.42 per share, then sold all 14,853 shares in open-market transactions at weighted average prices of $25.57 and $26.36 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan, and he reported no directly held common shares afterward while retaining 207,554 stock options following the option exercise.
Maze Therapeutics, Inc. chief business officer Atul Dandekar reported option exercises and related share sales. On May 29, 2026, he exercised stock options to acquire 7,500 shares of common stock at $10.42 per share and then sold 7,500 shares in open-market transactions at a weighted average price of $26.3405 per share. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025. After these transactions, he directly owned 24,808 shares of Maze Therapeutics common stock.
The Coloma trusts reported Rule 144 sales of MAZE common stock. The filing lists multiple dispositions by related trusts on including 116 shares on , 2,478 shares on , 1,822 shares on , 4,504 shares on , and 25,582 shares on , with corresponding gross proceeds shown.
Maze Therapeutics, Inc. director and CEO Jason V. Coloma reported indirect open-market sales of 32,564 shares of common stock, executed on May 22, 2026 and May 26, 2026.
The sales were made by the Coloma Family Trust and The Coloma 2021 Irrevocable Trust, where Coloma and his spouse serve as co-trustees. Reported prices were weighted averages around $26.00 per share, across multiple trades within narrow price ranges.
Following the latest transactions, the Coloma Family Trust held 350,987 shares and The Coloma 2021 Irrevocable Trust held 28,523 shares of Maze Therapeutics common stock. One of the transactions was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026, indicating a scheduled selling program rather than purely discretionary timing.
Maze Therapeutics, Inc. reported that Amy Bachrodt, its Senior Vice President of Finance, has given notice that she will resign effective June 1, 2026. The company states her resignation is not due to any disagreement regarding operations, policies, practices, or financial reporting. Following her departure, Chief Financial Officer Misbah Tahir will also serve as the company’s principal accounting officer, consolidating financial leadership under the CFO role.
Maze Therapeutics, Inc. director and Chief Executive Officer Jason V. Coloma reported open-market sales of common stock executed by family trusts associated with him. On May 15, 2026, The Coloma 2021 Irrevocable Trust sold 116 shares and the Coloma Family Trust sold 1,822 shares, each at $26.00 per share, for a total of 1,938 shares sold.
After these sales, the Coloma Family Trust held 381,073 shares of Maze Therapeutics common stock and The Coloma 2021 Irrevocable Trust held 31,001 shares. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted by Coloma.